Delivering on the Promise of Bioconjugates: from Engineering to Therapeutics
The field of Bioconjugates is a burgeoning area of research and holds promise beyond oncology and hematology. Leading the bioconjugates movement are Antibody-Drug Conjugates with 2 approved drugs on the market and over 30 molecules currently in clinical trials. Fusion Proteins are a well-established class of therapeutics and offer a promising alternative to antibody-based biologics. The Bioconjugates stream at PEGS delves into the optimization of ADCs and fusion proteins through novel linkers and payloads to increase specificity and efficacy, engineering the Fc region to improve PK, half-life and stability, as well as status updates on molecules currently in preclinical and clinical development.
Fusion Protein Therapeutics
Engineering ADCs
ADCs: Preclinical and Clinical Updates